Tissue Engineering and Regeneration Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Product (Biomaterials, Cell Therapy, Tissue Engineering), by Application (Orthopedics, Dermatology, Cardiology, Neurology, Others), by region, and Competition
Published Date: November - 2024 | Publisher: MIR | No of Pages: 320 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationTissue Engineering and Regeneration Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Product (Biomaterials, Cell Therapy, Tissue Engineering), by Application (Orthopedics, Dermatology, Cardiology, Neurology, Others), by region, and Competition
| Forecast Period | 2024-2028 |
| Market Size (2022) | 14.57 billion |
| CAGR (2023-2028) | 8.35% |
| Fastest Growing Segment | Tissue Engineering Segment |
| Largest Market | North America |
Market Overview
Global Tissue Engineering and Regeneration Market has valued at USD 14.57 billion in 2022 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 8.35% through 2028.
Key Market Drivers
High Demand for Organ Transplants
The demand for organ transplants far exceeds the supply of found at donor organs. This shortage of organs for transplantation has led to long waiting lists, and many patients may not receive a transplant in time. Tissue engineering offers a potential solution to address this organ shortage by creating lab-grown organs and tissues. Tissue engineering and regenerative medicine techniques involve growing functional organs and tissues in the laboratory using a patient's cells or other biocompatible materials. This approach provides an alternative source of organs for transplantation, reducing the dependence on donor organs. Tissue engineering allows for the creation of personalized organs that can be tailored to individual patients. This reduces the risk of organ rejection and the need for long-term immunosuppressive medications, which are necessary in traditional organ transplantation. Tissue engineering can create organs that are traditionally challenging to obtain from donors, such as vascularized organs, like hearts and kidneys. This expands the range of found at organs for transplantation.
Tissue-engineered organs have the potential to significantly reduce the waiting times for organ transplantation, increasing the chances of successful treatment for patients in need. Tissue-engineered organs can be designed with enhanced functionality, potentially outperforming natural organs in certain aspects. For example, engineered organs can be optimized for specific tasks, such as drug metabolism or tissue repair. Tissue engineering techniques can ensure better compatibility between the transplanted organ and the recipient's immune system. This reduces the risk of graft rejection and complications. Tissue engineering eliminates ethical concerns associated with organ trafficking and illegal organ trade. It also reduces the reliance on a complex and sometimes unreliable supply chain for donor organs. The demand for tissue-engineered organs has driven significant research and innovation in the field of regenerative medicine. Scientists are continually working to improve the techniques for growing functional organs and tissues. This factor will help in the development of the
Advancements in Stem Cell Research
Stem cells are undifferentiated cells with the unique ability to differentiate into various cell types, making them a crucial component in regenerative medicine. Pluripotent stem cells, such as human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs), are versatile and can differentiate into almost any cell type in the body. iPSCs are generated by reprogramming adult cells, making them a valuable resource for regenerative medicine research. Researchers have made significant progress in developing methods to guide the differentiation of stem cells into specific cell types, tissues, and organs. This directed differentiation is essential for producing functional tissues and organs for transplantation. Advances in 3D bioprinting technology enable the precise deposition of stem cells and biomaterials to create complex, three-dimensional structures. This technology has the potential to produce functional tissues and organs layer by layer. Researchers have developed techniques to create organoids, which are miniaturized, simplified versions of organs. Organoids can be derived from stem cells and serve as valuable models for studying tissue development and disease, as well as for drug testing. The emergence of gene editing tools like CRISPR-Cas9 has facilitated the modification of stem cells for specific purposes. Researchers can edit the genes of stem cells to enhance their regenerative potential or correct genetic defects before differentiation.
Exosomes, small vesicles secreted by stem cells, contain bioactive molecules that can influence tissue repair and regeneration. Stem cell-derived exosomes are being explored as a regenerative therapy without the need for direct cell transplantation. Researchers have successfully created functional organoids like mini-brains and mini-kidneys from stem cells. These organoids provide insights into organ development, disease mechanisms, and drug screening. The establishment of stem cell banks for different cell types has made it easier to access standardized and quality-controlled stem cell lines for research and clinical applications. Stem cell-based therapies are advancing in clinical trials and treatment settings. For example, mesenchymal stem cells are being used in orthopedics and tissue repair, while hematopoietic stem cell transplantation remains a standard treatment for certain blood-related disorders. Regulatory agencies are developing guidelines for the use of stem cell-based products and therapies to ensure their safety and efficacy. This regulatory clarity is essential for advancing stem cell therapies toward mainstream medical practice. Stem cells, especially iPSCs, have enabled the creation of disease-specific cell lines for studying the mechanisms of various diseases and screening potential drug candidates. This factor will pace up the demand of the Global Tissue Engineering and Regeneration Market.
Increasing Aging Population
As people age, they are more prone to degenerative diseases, such as osteoarthritis, Alzheimer's disease, cardiovascular disease, and age-related macular degeneration. These conditions often involve tissue and organ damage, making regenerative therapies a potential solution to address age-related health issues. Elderly individuals are more susceptible to chronic wounds, including pressure ulcers and diabetic foot ulcers. Regenerative approaches, such as advanced wound care and skin tissue engineering, play a critical role in wound healing and reducing complications in the aging population. The elderly frequently experience musculoskeletal problems, such as fractures, joint pain, and reduced mobility. Tissue engineering can offer solutions to repair or replace damaged bone and cartilage, promoting functional recovery and an improved quality of life. Aging is a major risk factor for cardiovascular diseases, which can lead to heart muscle damage. Regenerative therapies aim to repair damaged cardiac tissue, potentially improving heart function and extending the lives of older individuals. Age is a significant risk factor for neurodegenerative diseases, such as Alzheimer's and Parkinson's. Stem cell-based regenerative approaches hold promise for neural repair and the potential to slow the progression of these conditions.
Aging is associated with changes in the immune system, which can impact wound healing, tissue repair, and overall health. Regenerative approaches aim to enhance the body's ability to repair and regenerate tissues. Advancements in biomaterials have led to the development of implants and scaffolds that can be used in joint replacements, cardiovascular procedures, and tissue reconstruction, providing better options for elderly patients. Regenerative medicine can be tailored to individual patients, accounting for their unique health conditions and needs, which is particularly important for the aging population. Regenerative therapies offer the potential to enhance the quality of life for older individuals by addressing age-related health challenges and improving their overall well-being. As life expectancy continues to rise, there is a growing desire among the elderly to maintain an active and independent lifestyle. Regenerative medicine can support this by addressing age-related health issues and promoting healthy aging. Effective regenerative therapies can reduce the long-term healthcare costs associated with age-related diseases by addressing the root causes and potentially reducing the need for chronic medications and repeat surgeries. The increasing aging population has spurred research and development efforts in regenerative medicine to address the unique health needs of older individuals. This factor will accelerate the demand of the Global Tissue Engineering and Regeneration Market
Key Market Challenges
Long and Expensive Development Process
The development of regenerative therapies begins with extensive research and preclinical testing to understand the safety and efficacy of the proposed treatments. This stage can take many years and involve substantial financial resources. Clinical trials are a critical step in the development process to demonstrate the safety and effectiveness of regenerative therapies in humans. Conducting these trials involves a substantial investment, takes several years, and requires compliance with stringent regulatory requirements. Obtaining regulatory approvals from agencies like the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA) is a lengthy and costly process. Companies must meet rigorous standards and provide comprehensive data to prove the safety and efficacy of their therapies. Transitioning from small-scale laboratory production to large-scale manufacturing can be challenging. Ensuring consistent and cost-effective production of regenerative therapies is a complex task. Maintaining quality control and standardization throughout the manufacturing process is crucial. Deviations can lead to product inconsistency and may pose risks to patient safety. The development of regenerative therapies requires substantial financial resources, including funding for research, clinical trials, manufacturing facilities, and regulatory compliance. Raising this capital can be a barrier to entry for startups and smaller companies. Many regenerative therapies do not successfully make it to market. The high failure rate in clinical trials and the lengthy timelines contribute to the overall cost of development. The long development process can result in market uncertainties. By the time a therapy reaches the market, changes in the competitive landscape or evolving clinical standards can impact its commercial success.
Immunological Compatibility
When foreign tissues or engineered organs are transplanted into a patient, there is a risk of immune rejection. The recipient's immune system may recognize the transplanted tissue as foreign and mount an immune response to destroy it. To mitigate the risk of rejection, patients often need to take immunosuppressive drugs. These medications suppress the immune system to prevent it from attacking the transplanted tissue. However, long-term use of immunosuppressants can have side effects and increase the patient's susceptibility to infections and other health issues. In some cases, immunological incompatibility can lead to host vs. graft disease, where the recipient's immune system aggressively attacks the transplanted tissue, leading to graft failure. Allogeneic therapies, which involve using donor tissues or cells, often face immunological compatibility challenges. Finding a suitable donor with a closely matched immune profile can be difficult, and even with a close match, immune responses can occur. Achieving immunological compatibility is a key aspect of personalized medicine in regenerative therapies. Tailoring treatments to an individual's immune system requires extensive research and understanding of the patient's immune profile. Even with immunosuppression, the host vs. graft reaction can still occur. This reaction can lead to tissue damage and, in some cases, graft failure. Some tissue engineering and regenerative medicine strategies aim to develop strategies that do not rely on donor tissues or cells, thus bypassing immunological compatibility issues. This includes using the patient's own cells (autologous therapies) or universal donor cells.
Key Market Trends
Personalized Medicine
issue engineering and regenerative medicine aim to create therapies that are customized to each patient's unique needs. This approach can address individual variations in health, genetics, and disease. Induced pluripotent stem cells (iPSCs) are reprogrammed from a patient's own cells and can be used to generate patient-specific tissues and organs. This minimizes the risk of immune rejection and graft-versus-host disease. Advancements in genomics and molecular profiling allow for a detailed analysis of a patient's genetic and molecular characteristics. This information is used to guide treatment decisions and tailor regenerative therapies. iPSCs and patient-derived cells are used to create disease models, enabling researchers to study diseases in a patient-specific context. This is valuable for understanding disease mechanisms and testing potential treatments. Personalized regenerative therapies reduce the risk of immune rejection, as they are based on the patient's own cells. This minimizes the need for immunosuppressive drugs. By understanding a patient's genetic and molecular profile, clinicians can optimize the choice of tissue engineering and regenerative therapies. This ensures that the treatment is more likely to be effective and safe for the individual patient. Personalized medicine allows clinicians to predict a patient's response to specific therapies, helping to select the most appropriate regenerative approach for a better outcome. Personalized medicine places the patient at the center of care, emphasizing tailored treatments that consider the patient's unique biology, preferences, and needs. In some cases, companion diagnostics are used to identify the most suitable regenerative therapy for a patient based on their genetic or molecular profile.
Segmental Insights
Product Insights
In 2022, the Global Tissue Engineering and Regeneration Market largest share was held by Tissue Engineering segment and is predicted to continue expanding over the coming years.
Application Insights
In 2022, the Global Tissue Engineering and Regeneration Market largest share was held by orthopaedics segment and is predicted to continue expanding over the coming years.
Regional Insights
The North America region dominates the Global Tissue Engineering and Regeneration Market in 2022. North America, particularly the United States and Canada, has well-developed and advanced healthcare infrastructure. This includes state-of-the-art hospitals, research facilities, and a strong medical device industry, providing a conducive environment for tissue engineering and regenerative medicine. North America is home to many world-renowned universities and research institutions, which conduct cutting-edge research in the field of tissue engineering and regenerative medicine. These institutions often collaborate with the private sector, fostering innovation and development. The region hosts a significant biotechnology and pharmaceutical industry, with numerous companies engaged in the development and commercialization of regenerative therapies. This industry's presence contributes to advancements in the field. Government agencies, such as the National Institutes of Health (NIH) in the United States, provide substantial funding for research in regenerative medicine. This financial support helps drive innovation and the development of new therapies. North America has a well-established regulatory framework for medical products, including regenerative therapies. The U.S. Food and Drug Administration (FDA) plays a pivotal role in overseeing the approval and commercialization of these therapies, which often start with clinical trials in the region.
Recent Developments
- In March 2018, OrganogenesisInc., a prominent player in the regenerative medicine sector with a focus ondeveloping, manufacturing, and marketing advanced wound care, surgical, andsports medicine solutions, announced the introduction of a new, convenient 1.6cm disc size for its PuraPly Antimicrobial (AM) wound management product.PuraPly® and PuraPly AM are both FDA 510(k)-cleared Class II medical devicesdesigned for the management of acute and chronic wounds, catering to a widerange of wound types, including partial- and full-thickness wounds, pressureulcers, surgical wounds, trauma wounds, venous ulcers, and diabetic ulcers.These products are available in various sizes to suit the requirements of diversewound types. PuraPly AM employs an innovative technology, featuring a purifiednative collagen matrix infused with polyhexamethylene biguanide (PHMB), apotent broad-spectrum antimicrobial agent. This unique combination of nativecollagen and PHMB effectively addresses biofilm reformation while promoting thehealing process for a diverse array of wounds, regardless of their severity orduration.
- In October 2020, 3M hasunveiled the PREVENA RESTOR AXIO•FORM™ Incision Management System, specificallydesigned for the management of post-operative incisions and the surroundingsoft tissue envelope in the context of orthopedic surgical repair for lowerextremity fractures. The PREVENA RESTOR AXIO•FORM™ system plays a role instabilizing the incision site and the adjacent soft tissue, reducing edema, andcontributing to the improvement of post-operative recovery. This marks thethird addition to the PREVENA RESTOR™ Therapy portfolio, which was initiallyintroduced in 2019 to optimize post-surgical care and expand 3M's offerings inthe field of specialty surgical solutions. The primary objective of the PREVENARESTOR™ Incision Management System is to address surgical incisions thatcontinue to produce drainage after sutured or stapled closure by creating asealed environment and using negative pressure wound therapy to removeexudates.
Key Market Players
- Organogenesis Inc.
- Acelity L.P. Inc.
- Zimmer Biomet Holdings Inc.
- Stryker Corporation
- Integra LifeSciences Holdings Corporation
- Medtronic plc
- Smith & Nephew plc
- Athersys Inc.
- Vericel Corporation
- Osiris Therapeutics, Inc.
| By Product | By Application | By Region |
|
|
|
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy